ATE214613T1 - Zusammensetzungen, die einen guggul-extrakt mit phosphatsalzen enthalten - Google Patents

Zusammensetzungen, die einen guggul-extrakt mit phosphatsalzen enthalten

Info

Publication number: ATE214613T1
Authority: AT; Austria
Prior art keywords: phosphate; guggul extract; compositions containing; composition; phosphate salts
Prior art date: 1998-10-27

Application number

AT99308490T

Other languages

English (en)

Inventor

William Desisles Brink

Original Assignee

Prolab Nutrition Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-10-27

Filing date

1999-10-27

Publication date

2002-04-15

1999-10-27 Application filed by Prolab Nutrition Inc filed Critical Prolab Nutrition Inc

2002-04-15 Application granted granted Critical

2002-04-15 Publication of ATE214613T1 publication Critical patent/ATE214613T1/de

Links

239000000203 mixture Substances 0.000 title abstract 5
239000009437 guggulu extract Substances 0.000 title abstract 3
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical class OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 title 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
150000003013 phosphoric acid derivatives Chemical class 0.000 abstract 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 abstract 2
ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 abstract 1
241000124008 Mammalia Species 0.000 abstract 1
210000000577 adipose tissue Anatomy 0.000 abstract 1
230000037396 body weight Effects 0.000 abstract 1
239000001506 calcium phosphate Substances 0.000 abstract 1
229910000389 calcium phosphate Inorganic materials 0.000 abstract 1
235000011010 calcium phosphates Nutrition 0.000 abstract 1
239000002775 capsule Substances 0.000 abstract 1
235000012000 cholesterol Nutrition 0.000 abstract 1
229940089491 hydroxycitric acid Drugs 0.000 abstract 1
230000003516 hyperlipidaemic effect Effects 0.000 abstract 1
150000002632 lipids Chemical class 0.000 abstract 1
230000036651 mood Effects 0.000 abstract 1
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 1
229910000160 potassium phosphate Inorganic materials 0.000 abstract 1
235000011009 potassium phosphates Nutrition 0.000 abstract 1
239000001488 sodium phosphate Substances 0.000 abstract 1
229910000162 sodium phosphate Inorganic materials 0.000 abstract 1
235000011008 sodium phosphates Nutrition 0.000 abstract 1
230000002195 synergetic effect Effects 0.000 abstract 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 abstract 1
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 abstract 1
229960004441 tyrosine Drugs 0.000 abstract 1
238000004260 weight control Methods 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/32—Burseraceae (Frankincense family)
- A61K36/328—Commiphora, e.g. mecca myrrh or balm of Gilead
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Natural Medicines & Medicinal Plants (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Medical Informatics (AREA)
Mycology (AREA)
Inorganic Chemistry (AREA)
Hematology (AREA)
Diabetes (AREA)
Alternative & Traditional Medicine (AREA)
Biotechnology (AREA)
Botany (AREA)
Obesity (AREA)
Microbiology (AREA)
Psychiatry (AREA)
Child & Adolescent Psychology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Medicines Containing Plant Substances (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT99308490T 1998-10-27 1999-10-27 Zusammensetzungen, die einen guggul-extrakt mit phosphatsalzen enthalten ATE214613T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/179,328 US6113949A (en)	1998-10-27	1998-10-27	Weight control product and method of treating hyperlipidemia and increasing vigor with said product

Publications (1)

Publication Number	Publication Date
ATE214613T1 true ATE214613T1 (de)	2002-04-15

Family

ID=22656113

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99308490T ATE214613T1 (de)	1998-10-27	1999-10-27	Zusammensetzungen, die einen guggul-extrakt mit phosphatsalzen enthalten

Country Status (6)

Country	Link
US (1)	US6113949A (de)
EP (1)	EP0997149B1 (de)
AT (1)	ATE214613T1 (de)
CA (1)	CA2267488A1 (de)
DE (1)	DE69901051D1 (de)
GB (1)	GB2343115A (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP2002193818A (ja) *	2000-12-22	2002-07-10	Council Scient Ind Res	ググリピッドの新規使用法：認知エンハンサー、抗高血糖性の、及び皮膚の状態に関するものとして
US6485710B2 (en) *	2000-12-27	2002-11-26	Arthur Zuckerman	Appetite suppressant toothpaste
US6610277B2 (en) *	2000-12-27	2003-08-26	Arthur Zuckerman	Appetite suppressant toothpaste
EP1238590A1 (de) *	2001-03-09	2002-09-11	Unilever N.V.	Nahrungsmittelprodukt auf der Basis von Fett
AU2002344160A1 (en)	2001-05-29	2002-12-09	Unilever Plc	Food compositions for reducing insulin resistance
US6849278B2 (en) *	2001-11-21	2005-02-01	Universal Biotech Co., Ltd.	Method to counter oxidation of LDL, decrease triglyceride or cholesterol and inhibit atherosclerosis using Hibiscus sabdariffa extract
US6852342B2 (en) *	2002-03-26	2005-02-08	Avoca, Inc.	Compounds for altering food intake in humans
EP1578401A4 (de) *	2002-04-22	2009-03-25	Rtc Res & Dev Llc	Zusammensetzungen und verfahren zur förderung von gewichtsverlust, thermogenese, appetitzügelung, schlanker muskelmasse, erhöhung des stoffwechsels und verstärkung des energieniveaus, sowie verwendung als nahrungsergänzung für säugetiere
WO2003092614A2 (en) *	2002-05-02	2003-11-13	Hickle Randall S	Lipid removal from the body
US6565896B1 (en) *	2002-07-03	2003-05-20	Vitacost.Com, Inc.	Cholesterol treatment formulation
US20040253327A1 (en) *	2003-06-12	2004-12-16	Niazi Sarfaraz K.	Compositions and methods for reducing or controlling blood cholesterol, lipoproteins, triglycerides, and sugar and preventing or treating cardiovascular diseases
US20050025844A1 (en) *	2003-08-02	2005-02-03	Matthias Boldt	Weight control compositions and methods
US20050163872A1 (en) *	2004-01-23	2005-07-28	Cargill, Incorporated	Compositions and methods for reducing cholesterol
WO2006017211A1 (en) *	2004-07-12	2006-02-16	Research Development Foundation	Guggulsterone as an inhibitor of nuclear factor-kb and ikbalpha kinase activation
DE602005018384D1 (de) *	2004-10-22	2010-01-28	Nuxe Lab	Neuartige verwendung von chaulmoogra-öl und guggulipiden in therapeutika und kosmetika
FR2876912B1 (fr) *	2004-10-25	2007-04-20	Nuxe Sa Lab	Nouvelle utilisation de guggulipides en therapeutique et en cosmetique
US8287924B2 (en)	2011-03-17	2012-10-16	Sonia Pharma Gmbh	Treatment of menopausal symptoms as novel indication for myrrh

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4117120A (en) *	1977-02-11	1978-09-26	Elderbaum Gilbert J	Medication for herpes simplex and canker sores
US4364922A (en) *	1980-10-14	1982-12-21	University Of Virginia Alumni Patents Foundation	Adenosine antagonists in the treatment and diagnosis of A-V node conduction disturbances
US4592912A (en) *	1983-10-31	1986-06-03	Harriet Nickolaus	Ache and pain relieving and preventing composition
US4719111A (en) *	1985-06-14	1988-01-12	Wilson Lynn M	Novel composition for treatment of decubitus ulcers
US4713242A (en) *	1985-11-07	1987-12-15	Tecma Laboratories, Inc.	Skin therapeutic mixture containing eupatorium extract
US4847071A (en) *	1987-10-22	1989-07-11	The Procter & Gamble Company	Photoprotection compositions comprising tocopherol sorbate and an anti-inflammatory agent
US4847069A (en) *	1987-10-22	1989-07-11	The Procter & Gamble Company	Photoprotection compositions comprising sorbohydroxamic acid and an anti-inflammatory agent
US5011843A (en) *	1988-05-31	1991-04-30	Iolab Corporation	Treatment of glaucoma using phosphodiesterase inhibitors
DK339289D0 (da) *	1989-07-07	1989-07-07	Dak Lab As	Farmaceutisk praeparat
JPH0366623A (ja) *	1989-08-03	1991-03-22	Toreede Uindo Kk	肥満防止剤及びその製造法
EP0447706A1 (de) *	1990-03-22	1991-09-25	Cipla Limited	Verfahren zur Herstellung einer pharmazeutischen aktiven Mischung der Guggulsteronen Z und E
IT1247933B (it) *	1991-05-15	1995-01-05	Indena Spa	Estratti di commiphora mukul e loro applicazioni terapeutiche
US5238965A (en) *	1991-05-31	1993-08-24	The Procter & Gamble Company	Methods of using lysophosphatidic acids for regulating skin wrinkles
US5104676A (en) *	1991-06-27	1992-04-14	Abbott Laboratories	Weight control product
WO1993010756A1 (en) *	1991-11-25	1993-06-10	Richardson-Vicks, Inc.	Use of salicylic acid for regulating skin wrinkles and/or skin atrophy
EP0695181A1 (de) *	1993-04-20	1996-02-07	The Procter & Gamble Company	Verfahren zur verwendung von hesperetin zur sebumreduktion und behandlung von akne
US5494668A (en) *	1994-07-11	1996-02-27	Patwardhan; Bhushan	Method of treating musculoskeletal disease and a novel composition therefor
JP3396542B2 (ja) *	1994-07-22	2003-04-14	株式会社成幸社	固形上の痩身用食品
US5690948A (en) *	1997-01-10	1997-11-25	Elizabeth Arden Co., Division Of Conopco, Inc.	Antisebum and antioxidant compositions containing guguliped and alcoholic fraction thereof

1998
- 1998-10-27 US US09/179,328 patent/US6113949A/en not_active Expired - Lifetime
1999
- 1999-03-29 GB GB9907037A patent/GB2343115A/en not_active Withdrawn
- 1999-03-30 CA CA002267488A patent/CA2267488A1/en not_active Abandoned
- 1999-10-27 EP EP99308490A patent/EP0997149B1/de not_active Expired - Lifetime
- 1999-10-27 AT AT99308490T patent/ATE214613T1/de not_active IP Right Cessation
- 1999-10-27 DE DE69901051T patent/DE69901051D1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE69901051D1 (de)	2002-04-25
US6113949A (en)	2000-09-05
EP0997149A1 (de)	2000-05-03
EP0997149B1 (de)	2002-03-20
CA2267488A1 (en)	2000-04-27
GB9907037D0 (en)	1999-05-19
GB2343115A (en)	2000-05-03

Legal Events

Date	Code	Title	Description
2002-09-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
DE69901051D1 (de)	2002-04-25	Zusammensetzungen, die einen Guggul-Extrakt mit Phosphatsalzen enthalten
Harker et al.	1993	Interruption of vascular thrombus formation and vascular lesion formation by dietary n-3 fatty acids in fish oil in nonhuman primates.
Basu et al.	2003	Intestinal absorption in health and disease: micronutrients
BR0013677A (pt)	2002-05-14	Composições contendo metal, preparações e usos
Felsenfeld et al.	1999	Phosphorus, regulation of plasma calcium, and secondary hyperparathyroidism: a hypothesis to integrate a historical and modern perspective
CA2229077A1 (en)	1997-12-18	Lipid metabolism improving agent
WO2002002190A3 (en)	2003-08-28	Prevention and treatment of neurodegenerative diseases by glutathione and phase ii detoxification enzymes
DE69832710D1 (de)	2006-01-12	Nicht-irritierende zusammensetzung zur behandlung des aknes und andere hautzustände
DE69122099D1 (de)	1996-10-17	Zusammensetzung und verfahren zur prävention und behandlung von hypercholesterinämie und zellproliferationsstorungen
ATE254404T1 (de)	2003-12-15	Mehrteiliges nahrungsmittel, verfahren zu dessen herstellung und verwendung desselben
Chvapil	1975	Pharmacology of fibrosis: definitions, limits and perspectives
NZ541593A (en)	2009-05-31	Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis
ATE293367T1 (de)	2005-05-15	Nahrungszusammensetzungen enthaltend methionin
Nair et al.	1998	Impact evaluation of iron & iodine fortified salt
EP1341554A1 (de)	2003-09-10	Zusammensetzung auf colostrumbasis
ES2163472T3 (es)	2002-02-01	Caseinas micelarias fluoradas.
BG100911A (en)	1997-07-31	Biophosphonic acids-sontaining wet-granulated form
ATE413179T1 (de)	2008-11-15	Therapeutische verwendungen von steroiden bei blutzellmangelzustaenden
Otsuka et al.	2004	Effect of controlled zinc release on bone mineral density from injectable Zn‐containing β‐tricalcium phosphate suspension in zinc‐deficient diseased rats
WO2003020233A3 (de)	2003-11-20	Stabilisierung uv-empfindlicher wirkstoffe
JP2020528888A (ja)	2020-10-01	心血管器官の病態の予防及び処置における使用のための組成物
WO2000035952A3 (en)	2000-10-19	Compounds for control of eating, growth and body weight
ID27765A (id)	2001-04-26	Plester gel yang mengandung steroid dan proses pembuatannya
WO2001005356A3 (en)	2001-08-23	Weight control product comprising a synergistic mixture of guggul extract, phosphate salt and metabolic stimulant
AU1300001A (en)	2001-04-30	Gastroresistant tablets for alimentary, dietetic and therapeutic use